Scarica l'app Stockscreener
25.07
1.90%
-0.465
Dopo l'orario di chiusura:
25.06
-0.005
-0.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Pfizer Inc Borsa (PFE) Ultime notizie
Pfizer Stock (PFE) Today: 2026 Guidance Triggers Fresh Scrutiny—News, Forecasts, Analyst Targets and Dividend Outlook (Dec. 17, 2025) - ts2.tech
FDA Approves Brain Tumor Warning For Pfizer's Depo-Provera Amid Lawsuit - Benzinga
Pfizer: Ignoring The Dead Cat Bounce (NYSE:PFE) - Seeking Alpha
Pfizer: 2026 Feels Like Another Lost Year After Yesterday's Guidance Update (NYSE:PFE) - Seeking Alpha
Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future? - The Globe and Mail
Company News for Dec 17, 2025 - The Globe and Mail
Pfizer, Merck Are Boring Again: 2026 Investors Are Circling BackMerck & Co (NYSE:MRK), Pfizer (NYSE:PFE) - Benzinga
Nanobiotechnology Market to Hit USD 420.2 Billion by 2034, Fueled by 2025 Traffic Growth and Strategic Material & Product Innovations - GlobeNewswire Inc.
The Ultimate High-Yield Drug Stock to Buy With $1,000 Right Now - Finviz
Guggenheim maintains Buy rating on Pfizer stock, sets $35 price target - Investing.com Canada
Pfizer Stock (PFE) Slips After 2026 Outlook: Guidance, Analyst Forecasts, Dividend Update, and Key Catalysts to Watch on Dec. 17, 2025 - ts2.tech
Quintet Private Bank Europe S.A. Raises Position in Pfizer Inc. $PFE - MarketBeat
Pfizer, Astellas post late-stage trial win for Padcev in bladder cancer with Merck’s Keytruda - Seeking Alpha
Pfizer says phase 3 EV-304 clinical trial meets primary endpoint - marketscreener.com
Pfizer shares slide on pessimistic projections - The Pharma Letter
Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance - BioSpace
Wolfe Research Adjusts Price Target on Pfizer to $24 From $25, Maintains Underperform Rating - marketscreener.com
Pfizer stock price target lowered to $24 at Wolfe Research on underperformance - Investing.com Canada
Thrivent Financial for Lutherans Increases Stake in Pfizer Inc. $PFE - MarketBeat
Corient Private Wealth LLC Sells 179,789 Shares of Pfizer Inc. $PFE - MarketBeat
Assenagon Asset Management S.A. Purchases 3,722,531 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer Stock on the Edge: 3 Threats You Need to Know - Trefis
Pfizer : Analyst and Investor Call to Review Pfizer Full-Year 2026 Financial Guidance Transcript - marketscreener.com
Tilray Brands, Pfizer, Netflix, Lennar Corp. And Tesla: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Pfizer Stock (NYSE: PFE) News Today: 2026 Guidance, Earnings Forecasts, Analyst Price Targets and Key Catalysts - ts2.tech
Stock Market Today, Dec. 16: Pfizer Falls After Cutting 2025 Revenue Forecast - Yahoo Finance
Pfizer's Oncology and Obesity Pipelines Support a Narrow Moat Despite Looming Patent Expirations - Morningstar
Pfizer Stock After Hours Today (Dec. 16, 2025): PFE Drops on 2026 Outlook—What to Know Before the Market Opens Dec. 17 - ts2.tech
Pfizer (PFE) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Pfizer (NYSE:PFE) Stock Price Down 3.3% After Analyst Downgrade - MarketBeat
Pfizer Stands By Vaccines Investment Despite Political ‘Anomaly’ - Citeline News & Insights
Tepid 2026 outlook dents Pfizer shares - Yahoo Finance
Pfizer ’26 Guidance Puts Emphasis On The Long Term For A Return To Growth - Citeline News & Insights
Pfizer outlook, Humana leadership shake-up, Kraft Heinz's new CEO - Yahoo Finance
PFIZER INC : Jefferies reiterates its Buy rating - marketscreener.com
Pfizer Q4 2026 Financial Guidance (NYSE:PFE) 2025-12-16 - Seeking Alpha
Transcript : Pfizer Inc., 2026 Guidance/Update Call, Dec 16, 2025 - marketscreener.com
Market movers: Circle, Pfizer, Reconnaissance Energy Africa... - Proactive Investors
Pfizer's Muted 2026 Outlook Sends Ripples Through Pharmaceutical Sector - Markets Financial Content
Pfizer faces challenging years on fading COVID sales, margin pressure - Reuters
Pfizer forecasts 2026 profit below expectations on lower COVID product sales - WKZO
Pfizer leads COVID-19 vaccine peers lower after revamped guidance - Seeking Alpha
Pfizer (PFE): Reassessing Valuation After Cautious 2026 Outlook and Fading COVID-19 Revenue - Yahoo Finance
Pfizer sees flat 2026 sales as it rebuilds drug pipeline - The Detroit News
Pfizer trims 2026 profit forecast amid Covid headwinds and patent cliff pressures - Pharmaceutical Technology
Pfizer Stock (PFE) Slides After 2026 Guidance: COVID Sales Drop, Patent Cliff and Analyst Forecasts in Focus - ts2.tech
Rothschild & Co Redburn Adjusts Pfizer Price Target to $23 From $24, Maintains Neutral Rating - marketscreener.com
Pfizer shares fall after it forecasts 2026 revenue below estimates - Proactive Investors
Top Midday Stories: Pfizer Falls Following 2026 Outlook; Netflix-iHeartMedia Exclusive Deal; Apple's Possible iPhone Lineup Expansion - marketscreener.com
Pfizer CEO Defends Vaccines, Promises Growth by End of Decade - Barron's
Pfizer stock price target lowered to $27 at BofA on faster Covid product erosion - Investing.com Canada
Pfizer Forecasts Flat 2026 Sales as It Builds Drug Pipeline - Bloomberg.com
Why Pfizer (PFE) Stock Is Sliding Today - Yahoo Finance
Pfizer Shares Under Pressure Amid Financial Challenges - TipRanks
Pfizer Sees 2026 Profit Below Estimates as COVID Sales Decline - Yahoo Finance
Pfizer Shares Fall as 2026 Outlook Reflects Weaker COVID-19 Drug Demand - Tokenist
Pfizer sees weaker 2026 due to lower Covid-19 sales - Sharecast.com
PFE: Pfizer Stock Slides 3% After Lower 2026 Forecast - TradingView — Track All Markets
Herbert Smith Freehills Kewei advises Fosun Pharma on international licence agreements with Pfizer and Sitala - Legal Desire Media and Insights
Pfizer drops 3% on weak 2026 outlook - breakingthenews.net
PFIZER INC : JP Morgan is Neutral - marketscreener.com
Pfizer Sees Slower 2026 Growth Despite Pipeline Push, Cost Cuts - Benzinga
Pfizer Sets A Lower Bar For 2026 Earnings And Revenue - Finimize
Pfizer Issues 2026 Earnings Outlook Below Street Views, Expects COVID-19 Revenue to Decline - marketscreener.com
Pfizer : Analyst and Investor Call to Review Pfizer Full-Year 2026 Financial Guidance Event Announcement - marketscreener.com
2.10%
0.18%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):